Neurological And Neuropsychiatric Disorder

A significant proportion of patients who had COVID-19 experienced neurological and psychiatric morbidity in the 6 months following infection, according to results of a retrospective cohort study published in The Lancet Psychiatry.

The FDA has approved Caplyta for the treatment of schizophrenia in adults, according to a press release from the agent’s manufacturer.